Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dolin

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Archives of Internal Medicine|May 8, 1995
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials GroupR Dolin, D A Amato, M A Fischl, et al.
Journal of Virology|February 1, 1988
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccinesM H Snyder, R F Betts, D DeBorde, et al.
The Journal of Infectious Diseases|August 11, 1992
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials NetworkB S Graham, R B Belshe, M L Clements, et al.
JAMA|September 7, 1984
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infectionG J Mertz, C W Critchlow, J Benedetti, et al.
Journal of Clinical Pharmacology|March 1, 1992
Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complexS M Pai, U A Shukla, T H Grasela, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
The Journal of Infectious Diseases|June 1, 1994
Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosineT H Grasela, C A Walawander, M Beltangady, et al.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
Pediatrics|August 1, 1987
Children with influenza A infection: treatment with rimantadineC B Hall, R Dolin, C L Gala, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Archives of Internal Medicine|May 8, 1995
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials GroupR Dolin, D A Amato, M A Fischl, et al.
Journal of Virology|February 1, 1988
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccinesM H Snyder, R F Betts, D DeBorde, et al.
The Journal of Infectious Diseases|August 11, 1992
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials NetworkB S Graham, R B Belshe, M L Clements, et al.
JAMA|September 7, 1984
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infectionG J Mertz, C W Critchlow, J Benedetti, et al.
Journal of Clinical Pharmacology|March 1, 1992
Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complexS M Pai, U A Shukla, T H Grasela, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
The Journal of Infectious Diseases|June 1, 1994
Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosineT H Grasela, C A Walawander, M Beltangady, et al.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
Pediatrics|August 1, 1987
Children with influenza A infection: treatment with rimantadineC B Hall, R Dolin, C L Gala, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
Pageof 11